- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04975867
급성 중증 일산화탄소 중독에서 보조 표적 온도 관리
급성 중증 일산화탄소 중독에서 고압 산소 요법과 결합된 표적 온도 관리: 다기관 무작위 통제 임상 시험(TTM-COHB 시험)
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
연구 개요
상태
상세 설명
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, 대한민국, 26426
- Wonju Severance Christian Hospital
-
-
Incheon
-
Incheon, Incheon, 대한민국, 22332
- Inha University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ≥ 19 years.
- Patients who received HBO within 24 hours for acute CO poisoning.
- Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
- Signed informed consent prior to study entry.
Exclusion Criteria:
- Cardiac arrest before HBO
- Previous neurocognitive disorders
- Life-threatening underlying disease (ex: advanced cancer)
- Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
- Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
- No admission
- The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
- Pregnancy
- Burns
- More than moderate burn or Inhalation burn
- Burns complicated by other trauma
- Electrical burn
- Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Hypothermia group
Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
|
활성 비교기: Normothermia group
For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Main neurocognitive outcome
기간: At 6 months after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 6 months after CO poisoning
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Neurocognitive outcome
기간: At 1 month after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 1 month after CO poisoning
|
|
Cerebral Performance Category
기간: At 1 month and 6 months after CO poisoning
|
Cerebral Performance Category [range 1 - 5 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
modified Rankin scale
기간: At 1 month and 6 months after CO poisoning
|
modified Rankin scale [range 0 - 6 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
Glasgow outcome scale
기간: At 1 month and 6 months after CO poisoning
|
Glasgow outcome scale [range 1 (worst score) - 5] |
At 1 month and 6 months after CO poisoning
|
|
mini-mental status exam
기간: At 1 month and 6 months after CO poisoning
|
mini-mental status exam |
At 1 month and 6 months after CO poisoning
|
|
Korean version of the Modified Barthel Index
기간: At 1 month and 6 months after CO poisoning
|
Korean version of the Modified Barthel Index |
At 1 month and 6 months after CO poisoning
|
|
Mortality in intensive care unit
기간: Through study completion, an average of 6 months
|
Number of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
Mortality in intensive care unit
기간: Through study completion, an average of 6 months
|
Rate of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
In-hospital mortality
기간: Through study completion, an average of 6 months
|
Number of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
In-hospital mortality
기간: Through study completion, an average of 6 months
|
Rate of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
Mortality
기간: At 1, 3, and 6 months after CO poisoning
|
Number of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Mortality
기간: At 1, 3, and 6 months after CO poisoning
|
Rate of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Length of stay in intensive care unit and hospital
기간: Through study completion, an average of 6 months
|
Length of stay in intensive care unit and hospital |
Through study completion, an average of 6 months
|
|
Pneumonia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Pneumonia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
기간: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
S100ß (serum)
기간: Within 14 days after CO exposure
|
Concentration of S100ß (serum) |
Within 14 days after CO exposure
|
|
Neuronal specific enolase (serum)
기간: Within 14 days after CO exposure
|
Concentration of neuronal specific enolase (serum) |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
기간: Within 14 days after CO exposure
|
Number of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
기간: Within 14 days after CO exposure
|
Rate of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yong Sung Cha, MD, Wonju Severance Christian Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- TTM-COHB trial
- CR220011 (기타 식별자: Wonju Severance Christian Hospital)
- 2021-04-043 (기타 식별자: Inha University Hospital)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .